While it is nice to pump all RNAi companies people are forgetting something about RXII
ARWR and TKMR keep reaching new highs and it seems they have good delivery vehicles, but RXII still trades at such a low market valuation. I guess its good for those who are continuing to load up on RXII shares.
But investors seem to be forgetting something about RXI-109 and that is it is being sold right now in Europe to patients as a "Specials" designation under EMA law. The specials designation allows pharmaceutical companies to sell their drug to doctors provided that proper efficacy and safety is established.
With this in mind we can conclude that RXI-109 is proven to reduce scars in humans greater than placebo drugs which honestly do nothing, and that it is a very safe injection drug. What other RNAi company can claim it is being sold right now to doctors in Europe? We have something golden here with RXII and patience will win again IMO
This really does not bother me, or I bet Geert, TBH. You can only control what you do not what others do. You don't see me #$%$ about how ARIA has pumped #$%$ for 20 plus years and yet people still buy their stock.
Bio, we all know placebos do nothing, that is the essence of a placebo. As for the injection rxi-109, I think that is in the process of change. My take, if approved of course, the administration of the drug trough the skin will be much more passive so as to make it much more appealing to the patient.
Thus the association with Phosphagenics as we learned last week. A company whose specialty is the delivery of compounds to and through the skin. A number of companies use their technology, Novartis being one of them.
Dr. Cauwenbergh just last week was appointed a director of the company. No stone left unturned with this CEO.........................................